Compare Amphastar Pharmaceuticals Inc (AMPH) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Okta, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Okta, Inc. trades at $152.8 (market cap $26.20B). The key difference: Okta, Inc. is far larger — about 30.3× Amphastar Pharmaceuticals Inc's market cap, and Okta, Inc. is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | OKTA | |
|---|---|---|
Market Cap | $863.95M | $26.20B |
Sector | Health | Technology |
52-Week High | $30.81 | $154.62 |
52-Week Low | $16.87 | $62.93 |
Enterprise Value | $1.26B | $24.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
OKTA trades at $148.32, up 3.35% today, near its recent high of $157.00. The stock shows bullish momentum with consistent earnings beats, including Q1 2026 EPS of $0.91 versus $0.853 expected. Revenue growth is robust, rising from $1.3B in 2022 to $2.6B in 2025, with net income turning positive at $28M. Technical indicators signal bullish trends, while analyst consensus is strongly positive with 72.55% buy ratings.
Outlook is favorable due to strong cybersecurity demand and AI-driven product launches, but risks include high valuation (P/E of 107.48) and competition. Upside potential exists if earnings growth continues, with a consensus price target of $127.96 suggesting caution relative to current price. Investors should monitor Q2 2026 results on August 26, 2026, for confirmation of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
